IDENTIFICATION OF THE PHYSIOLOGICALLY RELEVANT ENDOGENOUS LIGAND FOR PPAR?

PPAR 的生理相关内源性配体的鉴定？

• 批准号: 8168779
• 负责人: Manu V. Chakravarthy
• 金额: $ 1.13万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-10 至 2010-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8168779
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Disease; Fatty-acid synthase; Funding; Gene Expression; Generations; Grant; Human; Institution; Ligands; Nuclear Receptors; PPAR alpha; Pharmaceutical Preparations; Research; Research Personnel; Resources; Source; United States National Institutes of Health; lipid metabolism

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The nuclear receptor PPARalpha is activated by drugs to treat human disorders of lipid metabolism. Its endogenous ligand is unknown. PPARalpha-dependent gene expression is impaired with inactivation of fatty acid synthase (FAS), suggesting that FAS is involved in generation of a PPARalpha ligand.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 核受体PPARalpha被药物激活以治疗人类脂质代谢紊乱。其内源性配体未知。PPARalpha依赖性基因表达随着脂肪酸合成酶（FAS）的失活而受损，表明FAS参与PPARalpha配体的产生。